These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 15477799

  • 1. [Statins: therapeutic cascade of their effects].
    Aronov DM.
    Kardiologiia; 2004; 44(10):85-94. PubMed ID: 15477799
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM.
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [Abstract] [Full Text] [Related]

  • 5. HDL-C: role as a risk modifier.
    Barter P.
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [Abstract] [Full Text] [Related]

  • 6. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A.
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [Abstract] [Full Text] [Related]

  • 7. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M.
    Am J Cardiovasc Drugs; 2010 Oct; 10 Suppl 1():3-9. PubMed ID: 21391728
    [Abstract] [Full Text] [Related]

  • 8. Beyond statins: what to expect from add-on lipid regulating therapy?
    Laufs U, Weintraub WS, Packard CJ.
    Eur Heart J; 2013 Sep; 34(34):2660-5. PubMed ID: 23832488
    [No Abstract] [Full Text] [Related]

  • 9. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R, Lenzi S.
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [Abstract] [Full Text] [Related]

  • 10. The evolving role of statins in the management of atherosclerosis.
    Vaughan CJ, Gotto AM, Basson CT.
    J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
    Laufs U.
    Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [How to manage lipid profiles and their interpretation in patients with coronary heart disease?].
    Farnier M.
    Presse Med; 2009 Jun; 38(6):958-63. PubMed ID: 19376680
    [Abstract] [Full Text] [Related]

  • 17. [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].
    Higashikata T.
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():628-36. PubMed ID: 15171447
    [No Abstract] [Full Text] [Related]

  • 18. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
    Rosenson RS, Tangney CC.
    JAMA; 1998 May 27; 279(20):1643-50. PubMed ID: 9613915
    [Abstract] [Full Text] [Related]

  • 19. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
    Järvisalo MJ, Toikka JO, Vasankari T, Mikkola J, Viikari JS, Hartiala JJ, Raitakari OT.
    Atherosclerosis; 1999 Dec 27; 147(2):237-42. PubMed ID: 10559508
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.